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ABSTRACT
Background: In preclinical models, antagonism of
metabotropic glutamate receptor 5 (mGluR5) reduces
transient lower oesophageal sphincter relaxations
(TLOSRs) and increases LOS pressure. This study
evaluated the effect of ADX10059, a potent, selective,
negative allosteric modulator of mGluR5, on oesophageal
pH-metry and clinical symptoms in GORD.
Methods: Two groups of patients with GORD (n=12 per
group) underwent 24-h oesophageal pH-metry on two
sequential treatment days. The patients received oral
placebo three times daily (tds) 30 min before a high-fat
meal on Day 1 and oral ADX10059 50 mg (Group 1) or
250 mg (Group 2) tds 30 min before a high-fat meal on
Day 2. The primary variable was acid exposure (%time
pH,4). Secondary variables included number and
duration of reflux episodes, number and duration of
symptomatic episodes and symptoms recorded in diaries.
Comparisons were made for Day 2 (active) versus Day 1
(placebo) treatment and for Group 1 versus Group 2.
Results: ADX10059 250 mg tds significantly decreased
the percentage of time with pH,4 from 7.2% to 3.6%
(p=0.01). ADX10059 250 mg tds reduced pH-metry-
measured oesophageal acid exposure, throughout the
24 h period, nocturnally and postprandially, and signifi-
cantly reduced the number and duration of symptomatic
reflux episodes (p=0.03). ADX10059 50 mg tds was not
significantly superior to placebo. ADX10059 was generally
well tolerated.
Conclusion: The mGluR5 negative allosteric modulator
ADX10059 reduced acid reflux which was associated with
improvement in clinical symptoms in patients with GORD.
ADX10059 appears to have a potential role in the clinical
management of GORD.
Proton pump inhibitors (PPIs) are the cornerstone
of medical therapy for gastro-oesophageal reflux
disease (GORD).
1–3 However, it has been estimated
that up to 30% of patients with GORD remain
symptomatic on standard dose (once daily) of
PPIs,
4–8 and the majority of these will continue to
experience GORD symptoms on even higher doses
of PPIs.
4–8 Hence, there is a need for novel
therapeutic approaches to GORD.
The most frequent mechanism underlying reflux
events is transient lower oesophageal sphincter
relaxation (TLOSR), which is an attractive target
for the treatment of GORD.
9 TLOSRs involve a
vago-vagal reflex pathway which is activated by
gastric distension and integrated in the brain stem
to result in relaxation of the lower oesophageal
sphincter smooth muscle. A wide variety of
transmitters and receptors are expressed centrally
and peripherally in the vagal pathway that
mediates lower oesophageal sphincter control.
9–11
Glutamate is the primary neurotransmitter
involved in signalling from visceral and somatic
primary afferents to the central nervous system.
11
Anatomical studies of vagal afferents have revealed
expression of metabotropic glutamate receptors
(mGluRs), including mGluR5, in the nodose ganglia
of several species, including humans, and evidence
suggests possible localisation in peripheral gastric
vagal afferent terminals.
11 Recent studies in animal
models identified selective antagonists of mGluR5 as
potent inhibitors of TLOSRs and reflux episodes.
12 13
It has been argued that peripheral mGluR5,
expressed in gastro-oesophageal vagal afferent end-
ings, plays a more prominent role in control of
TLOSRs as compared with central mGluR5.
10 These
preclinical findings support a role for mGluR5 in the
direct control over TLOSRs, providing a mechanistic
basis for the clinical development of mGluR5
antagonists for the treatment of GORD.
ADX10059 is a potent selective negative allos-
teric modulator of the mGluR5 receptor. Rather
than acting directly by blocking the glutamate
orthosteric binding site, ADX10059 modulates the
activity of the mGluR5 receptor by binding to a
site distinct from the glutamate binding site (ie, an
allosteric site), and diminishes the intra-cellular
signal created when glutamate binds to the
receptor. The inhibitory effects of a negative
allosteric modulator, unlike an orthosteric inhibi-
tor, are non-competitive. Hence, the magnitude
and duration of effect of a negative allosteric
modulator are not determined solely by its
pharmacokinetics. As the negative allosteric mod-
ulator acts dynamically with the natural ligand on
the receptor function, the effect is more a modula-
tion of physiological responses.
As well as being expressed in the gastrointestinal
tract, mGluR5 expression is predominant in areas
of the mammalian brain involved in emotional
processes, such as the dentate gyrus regions within
the hippocampus, regions of the basal ganglia
(striatum and nucleus accumbens) and in the
dorsal horn of the spinal cord, suggesting a role
for these receptors in affective disorders such as
anxiety and depression.
14 15 The mGluR5 is also
implicated in central pain processing pathways in
the trigeminal nucleus caudalis and spinothalamic
tract. ADX10059 is also centrally effective, and is
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on emotion centres and central pain processing may also be of
relevance in the symptomatic treatment of GORD. The present
study was a proof-of-concept study aimed at investigating the
efficacy, safety and tolerability of the selective mGluR5
antagonist ADX10059 in reducing acid reflux and clinical
symptoms in symptomatic patients with GORD.
MATERIALS AND METHODS
Study design and objectives
The study was a randomised, single (patient)-blind, placebo-
controlled, sequential treatment trial in patients with GORD.
The duration of the trial was approximately 4–5 weeks per
subject and comprised three visits: screening (Visit 1), two
consecutive study treatment days, (placebo followed by active
treatment, Visit 2), and a follow-up visit (Visit 3) 1–2 weeks
after dosing. As each patient received both placebo and active
treatment he/she acted as his/her own control.
The primary objective of the study was to explore the effect
of ADX10059 on oesophageal acid exposure measured by 24 h
oesophageal pH monitoring. The secondary objectives of the
study were: (1) to explore the effect of ADX10059 on diurnal,
nocturnal and postprandial episodes of acid reflux; (2) to
evaluate the effect of ADX10059 on clinical symptoms of reflux;
(3) to evaluate the safety and tolerability of ADX10059 in
patients with GORD; and (4) to evaluate the 0–4 h post-dose
plasma concentrations of ADX10059 in patients with GORD.
Conduct of the study
The study was conducted in a single centre (SGS Aster, Paris,
France) in an inpatient setting and was performed in accordance
with the ethical principles stated in the Declaration of Helsinki
as revised by 52nd General Assembly in Edinburgh, 2000, and
with the French Huriet law. After Ethics Committee approval,
the study was conducted between September and November
2006 in accordance with Good Clinical Practice (GCP) and
standard operating procedures (SOP) for clinical investigation
and documentation in force at the clinical trial centre.
Patients
The patients were recruited from a specialist gastroenterology
clinic in Paris. All patients had a prior diagnosis of symptomatic
GORD made by a gastroenterologist and all had to have a
history of good control of heartburn, regurgitation and other
GORD symptoms with acid suppressant therapy. Patients who
were on acid suppressants at the time of screening had to stop
treatment for at least 2 weeks before the study treatment days.
Eligible patients were Caucasian men and women aged 18–65
years, weighing between 50 and 100 kg with a body mass index
between 18 and 35 kg/m
2, who were non-smokers or light
smokers (,5 cigarettes per day), with normal arterial blood
pressure and heart rate.
Patients were excluded if they (1) had any clinically
significant acute or chronic disease or significant abnormality
in pre-study laboratory tests and physical examination; (2) had
received any experimental drug within 30 days prior to screen-
ing; (3) were known or suspected alcohol or drug abusers;
(4) had undergone surgery or had donated blood within
1 month prior to study start; or (5) had received any drug
known to affect hepatic metabolism within 1 month or any
drug known to affect renal tubular secretion or gastrointestinal
motility, within 2 weeks prior to the first study dose admin-
istration. Patients with a history of oesophageal stricture,
gastrointestinal bleeding or gastrointestinal surgery were also
excluded.
Figure 1 Patient disposition.
Table 1 Demographic characteristics of the patients
Characteristic Group 1 (n=12) Group 2 (n=12)
Race (Caucasian) 12 (100%) 12 (100%)
Sex (female) 3 (25%) 2 (16.7%)
Age (years) 44.6 45.1
Weight (kg) 77.9 79.8
Body mass index (kg/m
2) 26.1 26.2
Light smokers (,5 cigarettes/day) 3 (25.0%) 2 (16.7%)
Previous GORD medications 6 (50%) 10 (83.3%)
GORD, gastro-oesophageal reflux disease.
Oesophagus
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Screening and randomisation
Within3 weeksofthefirststudytreatmentdaypatientsattendeda
screening visit. After patients had provided their written informed
consent,themedicalhistoriesanddemographicdatawererecorded
and safety screening was performed. Eligible patients were
randomised to one of two treatment groups: Group 1, placebo
(Study Day 1) followed by ADX10059 50 mg tds (Study Day 2); or
Group2,placebo(StudyDay1)followedbyADX10059250 mgtds
(Study Day 2). The choice of doses was based on the pharmaco-
kinetic and tolerabilitydatafrom a previous repeated dose study in
healthy subjects (ref study ADX10059-102, data on file), using the
same immediate release formulation; ie, simple drug powder-filled
capsules with no excipients.
Study drug dosing and pH monitoring days
Patients were admitted to the clinical pharmacology unit on the
evening prior to study drug dosing (ie, Day 21). Prior to dosing
on Study Days 1 and 2, patients fasted overnight for a
minimum of 10 h. Standardised high-fat meals were provided
for breakfast, lunch and supper and patients had 30 min to
consume each meal. To normalise intake, a fixed amount of
water (1500 ml) was supplied and was required to be consumed
within each 24 h period. The ambulatory oesophageal pH
monitoring was performed using an antimony pH electrode with
a separate skin reference electrode (Digitrapper pH100;
Medtronic, Tolochenas, Switzerland). The ambulatory pH
monitoring unit was calibrated before each use, using standard
buffers. The oesophageal pH probe was inserted via one nostril to
a distance of approximately 5 cm above the lower oesophageal
sphincter. Online continuous pH monitoring was used to locate
the position of the lower oesophageal sphincter for each patient.
On Study Days 1 and 2 the probe was inserted and monitoring
started about 10 min prior to the first dose administration. The
probe was removed after approximately 24 h. Patients had a
30 min pH monitoring-free period, with removal of the catheter,
between the two study days so that they could take a shower and
change their clothes if they wished.
On each study day, the patients were administered a single
oral dose of study medication on three occasions, 30 min before
each meal. On Study Day 1 they received placebo, and on Study
Day 2 they received ADX10059 50 mg (Group 1) or 250 mg
(Group 2). The patients took the capsules with 240 ml of water
at room temperature and were dosed while standing. After
dosing, the patients remained on their beds, sitting at
approximately 45 degrees. The patients were not allowed to
lie flat for 4 h following the morning and midday doses, except
for study procedures or if clinically indicated.
The timetable of procedures on Study Days 1 and 2 was as
follows:
c 07:20 start oesophageal pH recording
c 07:30 study medication dose 1
c 08:00 breakfast
c 12:30 study medication dose 2
c 13:00 lunch
c 19:30 study medication dose 3
c 20:00 dinner
c 22:00 to approx 07:00 bedtime
c 07:00 approx, end of pH monitoring period on Day 1 (on
Day 2 end of pH monitoring period was at 07:30)
Pharmacodynamic efficacy measures
24 h oesophageal pH measurement
Oesophageal pH was recorded for approximately 24 h starting
on Study Day 1 and Study Day 2. pH measurements were
captured every 4 s resulting in approximately 21 600 measure-
ments for each 24 h period. Each variable was calculated for the
24 h recording period and for the upright diurnal period (07:30
to 22:00) and the supine nocturnal period (22:00 to 07:30
approx). The percentage time for oesophageal pH,4 was
calculated from the continuous online monitoring.
Number and duration of reflux episodes
The number and total duration of gastro-oesophageal reflux
episodes was recorded. In accordance with the standards of the
clinical pharmacology unit, a reflux episode was defined as
seven consecutive measures with a pH,4; ie, at least 28 s. The
total duration of reflux episodes was the sum of all actual times
of reflux episodes >28 s. The number of gastro-oesophageal
reflux episodes and the total duration of time with gastro-
oesophageal reflux episodes was summarised for the 24 h,
diurnal and nocturnal periods. Oesophageal acid clearance was
expressed as the mean duration of acid reflux events.
Postprandial reflux episodes
The postprandial periods were defined as the period of 4 h
following each meal; ie, from 08:00 to 12:00, 13:00 to 17:00 and
Table 2 Percentage time when the pH was less than 4
Treatment group
Percentage time
pH,4i n2 4h
Percentage time
pH,4, diurnal
Percentage time
pH,4, nocturnal
Group 1, n=12
Placebo 14.9 9.5 22.7
ADX10059, 50 mg 15.1 12.8 18.9
Estimate change from baseline 2.71 4.75 0.19
95% Confidence interval 22.05 to 7.48 0.14 to 9.37 25.88 to 6.26
p Value NS 0.0442* NS
Group 2, n=11
Placebo 7.2 5.2 9.7
ADX10059, 250 mg 3.6 3.4 3.7
Estimate change from baseline 26.41 23.41 210.37
95% Confidence interval 211.4 to 21.42 28.24 to 1.42 216.73 to 24.01
p Value 0.0144 NS 0.0028
*Increased compared with placebo.
NS, not significant.
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pH drop to ,4 for at least 28 s and as food has an effect on
neutralising stomach acid, pH drops >1 for at least 28 s were also
used to measure postprandial reflux. The number and duration of
postprandial reflux events were summarised for each treatment.
In addition, the number and total duration of pH drops >1w e r e
summarised for the 24 h and nocturnal periods.
Clinical symptoms of reflux
Patients recorded the occurrence and duration of symptomatic
reflux episodes in a diary on each treatment day. Patients were
asked to note when they experienced typical GORD symptoms.
Heartburn and regurgitation were not evaluated separately. The
number and duration of symptomatic reflux events were
summarised for the 24 h period.
Safety and pharmacokinetic measures
Safety assessments were made at screening, at follow-up and at
regular time points during the study drug administration days.
The safety measures comprised full physical examination,
urinalysis, pregnancy testing (screening and follow-up only),
heart rate, blood pressure, haematology, biochemistry, 12-lead
ECG and regular adverse events enquiry.
Blood samples for plasma concentrations of ADX10059 were
taken on both study days (to maintain the blinding to the
patient) pre-dose and at 0.5, 1.0, 2.0, 3.0 and 4.0 h after each
dose. From the plasma concentration versus time profiles the
following pharmacokinetic parameters were assessed: tmax,
Cmax, AUC0–4 and AUC0–‘.
Statistical methods
The primary efficacy variable was the percentage of time with
oesophageal pH,4 comparing ADX10059 with placebo.
Secondary variables included: (1) the percentage of time with
oesophageal pH,4 in the nocturnal and diurnal periods; (2) the
number and duration of reflux episodes (oesophageal pH,4)
during the 24 h, nocturnal, and the 4 h postprandial periods;
(3) the number and total duration of pH drop >1, during the
24 h, nocturnal and the 4 h postprandial periods; (4) oesopha-
geal acid clearance; and (5) the number and total duration of
symptomatic episodes of GORD.
The analysis populations were as follows. The safety
population included all randomised patients, who received the
study drug and had post-dosing data. The pharmacodynamic
population included all patients who completed the study
without major protocol violations or events implying a bias for
pharmacokinetic evaluation and with two complete pH-metry
profiles (Study Days 1 and 2).
Intra-individual comparison between placebo and active drug
was performed during the two successive assessments. Statistical
analysis for efficacy was performed on the pharmacodynamic
population. For the primary and secondary endpoints, all
parameters were analysed on the change from baseline (placebo
day 1 value)by analysis of covariance (ANCOVA) using doselevel
as a fixed effect and baseline as covariate. Estimates (least squares
means) of dose effects and differences between doses were
provided with their respective 95% confidence intervals.
Quantitative parameters were described per group, dose level
and time point using n (number of observations), mean, median,
standard deviation (SD), minimum, and maximum. The 95%
confidence interval of the mean was included for changes from
baseline. All statistical tests were two-tailed and the significance
threshold was set at the 5% level.
This was an exploratory study without a formal statistical
sample size calculation. A total of 12 patients per dose group
was deemed to be sufficient to obtain meaningful data on the
pharmacodynamic effect of ADX10059 on 24 h pH and clinical
symptoms in this proof-of-concept study.
RESULTS
Patient demographics
Thirty-two patients were screened, of which 24 were rando-
mised (eight were not eligible, four had abnormal laboratory
values, three withdrew consent and one had an abnormal ECG).
All 24 randomised patients (12 in Group 1 comparing
ADX10059 50 mg to placebo, and 12 in Group 2 comparing
ADX10059 250 mg to placebo) completed the study and were
Table 3 Group 1 (ADX10059 50 mg tds): number and duration of reflux episodes and clinical symptoms
Efficacy variable
ADX10059 50 mg tds,
(n=12)
Placebo tds,
(n=12) p Value
Mean (SD) number reflux episodes
(pH,4) in 24 h
65.3 (48.9) 51.9 (43.3) NS
Mean (SD) total duration of reflux episodes
(pH,4) in 24 h (min)
185.3 (136.4) 184 (172.6) NS
Mean (SD) number nocturnal reflux
episodes (pH,4)
28.6 (26.9) 21.4 (20.7) NS
Mean (SD) total duration of reflux episodes
(pH,4) nocturnal period (min)
97.1 (76.6) 118 (113.3) NS
Mean (SD) number of symptomatic
episodes
5.3 (3.3) 6.6 (4.6) NS
Mean (SD) duration of symptomatic
episodes (min)
28.7 (43.9) 43.2 (81.0) NS
NS, not significant; tds, three times daily.
Figure 2 Mean total duration of reflux episodes.
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patient in Group 2 was excluded from the pharmacodynamic
population due to missing pH-metry data on Study Day 1 when
his pH probe became displaced. Subject disposition is shown in
fig 1. The treatment groups had similar demographic and
baseline characteristics (table 1).
The majority of the patients were men (nine in Group 1 and
10 in Group 2) with an average age of approximately 45 years.
In Group 1 50% of patients and in Group 2 83% of patients,
were previously using regular acid suppression therapy.
Primary efficacy: percentage of time pH,4i n2 4h
Atbaseline,patientsinGroup1tendedtohaveagreaterpercentage
of time pH,4 in the 24 h period, but this difference was not
significant (14.9 (SD 13.9)% Group 1; 7.2 (SD 5.8)% Group 2, p =
NS). There was no significant effect of ADX10059 50 mg tds on
percentage of time pH,4 (table 2). ADX10059 250 mg tds
significantly decreased the percentage of time that pH was ,4i n
the 24 h period to 3.6 (SD 3.2)% (p=0.0144) and in the nocturnal
period from 9.7 (SD 10.2)% to 3.7 (SD 6.0)% (p=0.0028).
Secondary efficacy measures
Number and duration of acid reflux episodes: 24 h and nocturnal
periods
At baseline, there were no significant differences between the
treatment groups for either the number or total duration of
gastro-oesophageal acid reflux episodes during the 24 h period.
Compared with placebo, ADX10059 50 mg t.i.d. in Group 1 did
not significantly alter the mean number of acid reflux episodes or
the total duration of episodes, in all time periods (table 3). The
average oesophageal acid clearance was not altered by ADX10059
50 mg tds (3.9 (SD 0.4) vs 3.4 (SD 0.4) min; NS).
In Group 2, ADX10059 250 mg tds significantly decreased the
mean total duration of acid reflux episodes during the 24 h period
(mean 40 (SD 39) vs placebo 86 (SD 72) min p=0.0132) and
during the nocturnal period (mean 16 (SD 29) vs placebo 49 (SD
54) min, p=0.0021) (fig 2). There was also a trend towards a
decreaseinthenumberofepisodesofacidrefluxatalltimepoints,
but the differences were not statistically significant (table 4). The
average oesophageal acid clearance was not significantly altered
by ADX10059 250 mg tds (3.0 (SD 0.3) vs 2.4 (SD 0.3) min, NS).
Total duration pH drops >1: 24 h and nocturnal
Overall, in Group 2 there was a reduction in the total duration
of pH drop >1 in 24 h, from a mean of 118 (SD 57) min with
placebo to a mean of 75 (SD 46) min during active treatment
(p=0.054) of which the nocturnal duration significantly
decreased from a mean of 58 (SD 42) min to a mean of 31
(SD 34) min (p=0.0049).
In Group 1, the 50 mg dose of ADX10059 did not
significantly alter the number or duration of pH drops >1i n
the postprandial periods, the nocturnal or the 24 h period.
Postprandial reflux
InGroup1,the50 mgdoseofADX10059didnotsignificantlyalter
the number or duration of reflux episodes using either oesophageal
pH,4, or pH drops >1, in the 4 h postprandial periods.
Using pH drops >1, in Group 2 ADX10059 250 mg tds
significantly decreased either the number or duration of reflux
episodes in the postprandial periods.
The number of drops of pH>1 significantly decreased in the
post-breakfast period (mean 6.8 (SD 5.4) vs placebo 9.7 (SD 4.0),
p=0.041). Post-lunch and post-dinner the differences in the
number of episodes of pH drops >1 were not statistically
significant. The duration of pH drops >1 significantly decreased
in the post-lunch period (mean 8.1 (SD 5.3) vs placebo 15 (SD
8.3) min, p=0.0371) and post-dinner period (mean 5.1 (SD 4.6)
vs placebo 13.5 (SD 9.7) min, p=0.0146) (fig 3).
In Group 2, using oesophageal pH,4 to determine post-
prandial reflux, ADX10059 showed a numerical reduction in the
number and duration of episodes but none achieved statistical
significance.
Clinical symptoms of reflux
The mean number of patients who reported symptomatic reflux
episodes was significantly lower than the total number of reflux
episodes detected by pH monitoring.
Table 4 Group 2 (ADX10059 250 mg tds): number and total duration of reflux episodes and clinical
symptoms
Efficacy variable
ADX10059 250 mg tds,
(n=11)
Placebo tds,
(n=11) p Value
Mean (SD) number reflux episodes
(pH,4) in 24 h
20.5 (19.4) 32.7 (20.3) NS
Mean (SD) total duration of reflux episodes
(pH,4) in 24 h (min)
39.9 (38.7) 86 (72.2) 0.0132
Mean (SD) number nocturnal reflux
episodes (pH,4)
6.4 (9.9) 13.6 (12.3) NS
Mean (SD) total duration of reflux episodes
(pH,4) nocturnal period (min)
16.4 (29) 48.7 (54) 0.0021
Mean (SD) number of symptomatic
episodes
1.9 (3.8) 7.0 (13.8) 0.031
Mean (SD) duration of symptomatic
episodes (min)
5.2 (12.6) 13.9 (20.1) 0.031
tds, three times daily.
Figure 3 Mean duration of postprandial episodes of pH drop .1.
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reduction in the number and duration of symptomatic reflux
episodes (table 4). The number of episodes was reduced from 7
(SD 13.8) on the placebo baseline day to 1.9 (SD 3.8) on the active
treatment day (p=0.031) and the mean total duration of
symptomatic reflux was reduced from 13.9 (SD 20.1) to 5.2 (SD
12.6) min (p=0.031) In the ADX10059 50 mg group, the number
of symptomatic episodes was not significantly reduced (table 3).
Pharmacokinetics
The mean plasma concentration–time curves are shown in fig 4.
Following oral administration, ADX10059 was rapidly absorbed
and was detectable in plasma 30 min after dosing in the
majority of patients. There was inter-individual variability in
plasma exposure (coefficient of variation of approx 50% for both
doses for AUC0–16). For ADX10059 50 mg, the geometric mean
Cmax ranged from 27.3 ng/ml after dose 1 to 35.4 ng/ml after
dose 3; and for ADX10059 250 mg, ranged from 221 ng/ml after
dose 1 to 283 ng/ml after dose 3. The time to reach maximum
plasma concentration was variable and ranged between 0.5 and
4 h regardless of dose and administration number.
Correlations of plasma concentration with reflux episode
duration in the whole 24 h period and in each of the
postprandial periods were performed. Although the drug effect
seems to increase with increasing ADX10059 dose, no clear
pharmacodynamic/pharmacokinetic relationship could be seen.
Safety and tolerability
ADX10059 given as three doses in 1 day was generally well
tolerated by the patients with GORD. No serious adverse events
were reported. One patient in Group 1 reported flatulence after
receiving placebo. The incidence of adverse events was higher in
Group 2, the 250 mg tds group, 11/12 (91.6%) than in the 50 mg
t.i.d. group 2/12 (16.7%). In Group 1, somnolence, cough and
rhinorrhoea were reported in 1/12 patients (8%). In Group 2, the
most commonly reported adverse events were related to the
central nervous system and the most common single adverse
event was dizziness (9/12 patients, 75%). The dizziness was
accompanied by nausea in 4/12 (33%) of the patients. In
addition, 2 (17%) patients reported dysuria and other events
occurring in 1/12 (8%) patients were tinnitus, visual accom-
modation disorder, dry mouth, vomiting, paresthesia,
hypoesthaesia, feeling drunk and hot flush. All adverse events
except one occurred following the first or second dose; none of
the events was described as severe and all resolved without
sequelae. No clinically significant changes in safety monitoring
parameters for haematology, blood chemistry, urinalysis, vital
signs, physical examination or 12-lead ECG were reported.
DISCUSSION
Inhibition of mGluR5 has been shown to reduce transient lower
oesophageal sphincter relaxation episodes and increase lower
oesophageal sphincter tone in animals,
12 13 a mechanism which
could have application in the prevention of gastro-oesophageal
reflux in humans. To our knowledge, the effect of mGluR5
inhibition on TLOSRs and reflux events has not been reported
in humans. The aim of the present study was to assess the effect
of ADX10059 on gastro-oesophageal reflux in patients with
GORD, using pH-metry to detect episodes of acid reflux and
hence indirectly study LOS function.
To this end, 24 patients with GORD diagnosed in a specialist
gastroenterology clinic were randomised in two groups of 12
patients (Groups 1 and 2). In each group, the effect of
ADX10059 (50 mg tds or 250 mg tds for 1 day) was compared
with placebo. The doses of ADX10059 were selected based upon
the pharmacokinetic and tolerability data from a previous
repeated dose study in healthy subjects (ref study ADX10059-
102 data on file). The upper and lower extremes of the doses
from that study were chosen for this study to explore the
safety, tolerability and pharmacodynamics across a dose range
that might have therapeutic potential in patients with GORD.
In both groups, each patient received placebo treatment on Day
1 and then ADX10059 on Day 2 in a single-blind fashion, and
therefore acted as his/her own control. Patients were blinded as to
the treatment sequence so that they could objectively evaluate
their clinical symptoms on each treatment day.
Consistent with previous results obtained with the immedi-
ate release, powder-filled capsule, ADX10059 was quite rapidly
absorbed with a median plasma peak occurring between 1.0 and
2.0 h following administration. As already observed in healthy
subjects, there was a large inter-individual variability for plasma
concentrations and pharmacokinetic parameters. No clear
relationship was drawn from the review of drug exposure and
drug effect. The safety and tolerability profile was also
consistent with that observed at these doses in previous single
and repeated dose studies of ADX10059 in healthy subjects
(refs. Data on file, studies ADX10059-101, 102 and 103). The
central nervous system effects (eg, dizziness) seen in the 250 mg
tds group are consistent with the mechanism of action and the
rapid absorption following dosing using the immediate release
capsule. The side effect profile in the higher dose group is
considered undesirable for long-term treatment of GORD, there-
fore a modified release formulation which is less rapidly absorbed
and which has been shown to reduce the occurrence of central
nervous system side effects (data on file Study ADX10059-104),
has been developed and will be used for subsequent studies. While
the 50 mg of ADX10059 tds had no statistically significant effect,
the 250 mg dose of ADX10059 tds produced significant improve-
ment in pH-metry-derived reflux and in the symptomatic
expression of GORD. To our knowledge, this is the first study
in humans to support the findings of previous animal studies on
the effect of mGluR5 antagonism on reflux events. Hence the
concept that the mGluR5 negative allosteric modulator (NAM)
may reduce reflux and have therapeutic potential in GORD was
supported by the findings of this study.
Based on animal studies with other mGluR5 NAMs,
3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) and
2-methyl-6-phenylethynylpyridine (MPEP), the effects of
ADX10059 on oesophageal acid exposure are expected to reflect
inhibition of TLOSRs through a peripheral mode of action.
10
The decrease in acid reflux events in the postprandial period,
when TLOSRs occur most frequently,
9 is compatible with such
a mechanism of action. It is less clear whether the inhibition of
nocturnal reflux events is also attributable to inhibition of
TLOSRs, or whether other factors, such as an increase in resting
LOS pressure which was apparent from animal studies using
MTEP and MPEP,
12 may play an additional role. Inhibition of
nocturnal reflux has also been observed with baclofen, which
inhibits TLOSRs through c-amino butyric acid type B receptor
agonism.
91 61 7 Although the 250 mg dose of ADX10059 sig-
nificantly decreased the total duration of acid reflux events, this
was not associated with a significant decrease of the number of
reflux events for the 24 h measurement period. This observation
suggests shortening of reflux episodes, which could be due to
improved oesophageal clearance (although this was not
observed in this study) or to a smaller volume of refluxed
material during reflux events. Elucidating the mechanisms
Oesophagus
Gut 2009;58:1192–1199. doi:10.1136/gut.2008.162040 1197underlying the anti-reflux effects of ADX10059 will require
additional studies.
This study was an initial exploratory study and as such the
authors recognise that there are features of the design which
could potentially impact the interpretation of the results and for
which the rationale should be explained. A single-blind
sequential day dosing regimen was chosen principally for
logistic reasons, so that the patients would not have to undergo
pH monitoring for an extended duration or have to undergo
repeated admissions to the unit, which would have been
required if the study had been a randomised cross-over design.
The patients were blinded to the treatment sequence and
underwent exactly the same procedures on Study Days 1 and 2
(including blood sampling for pharmacokinetics) in order to
minimise any effect on subjective symptom reporting. As the
majority of evaluations were objective physiological measures,
the single-blind design should not affect these. However, it is
possible that the measures on Study Day 2 could differ to those
on Study Day 1 due to the study conditions and it would
normally be preferable to randomise the treatment order to
mitigate this. Overall,using the 250 mgdose, significant decreases
in acid reflux parameters and in reflux-related symptoms were
observed. Although oesophageal pH monitoring shows consider-
able intra-individual day-to-day variability, systematic order
effects with lower acid exposures on Study Day 2 are not
found.
18–27 Also, the consistent effects in the 250 mg dose group
were not seen in the 50 mg dose group suggesting a dose response
effect. Hence the study design is not considered to significantly
impact the overall interpretation of the results.
The definition of reflux events as seven consecutive episodes
of oesophageal pH,4 was one that was standard for the clinical
pharmacology unit. It is recognised that this may lead to under-
reporting of the number of reflux events and only acid reflux
events can be captured in this way. The total percentage of
pH,4 was derived from the continuous pH monitoring and so
reflux events that were less than 28 s were captured in this
measurement. Furthermore, as food may neutralise the stomach
pH, drops in pH of >1 for >28 s were used, in addition to the
measure of pH,4 for >28 s, to more accurately identify
postprandial reflux events. Impedance pH monitoring is a more
sensitive measure of reflux events capturing all types of reflux
event and this will be used for subsequent studies.
CONCLUSIONS
To our knowledge, this is the first study to report on the effects
of a mGluR5 NAM in patients with GORD. ADX10059 250 mg
tds reduced acid reflux as measured by pH-metry, and this was
associated with improvement in clinical symptoms. The study
confirms the potential for the mGluR5 NAM ADX10059 in the
treatment of GORD. Potential therapeutic applications to be
evaluated include add-on therapy in patients with GORD with
incomplete response to PPIs, or monotherapy in those for whom
PPIs are unsuitable.
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ANSWER
From the question on page 1176
The patient was referred to surgery for a suspected submucosal
gastric intestinal stromal tumour (GIST) that was arising from
the muscularis layer of the gastric wall. Intraoperatively, the
mass was found to be adherent to the undersurface of the left
lobe of the liver which mandated an en bloc left lateral
segmentectomy and wedge gastrectomy. Pathological examina-
tion of the resected specimen confirmed heterotopic pancreatic
tissue in the gastric wall, composed of pancreatic acini and ducts
with no islets, involving the submucosa and muscularis propria
with an intact overlying mucosa (fig 1). The pancreatic tissue
displayed all the changes of acute pancreatitis. Heterotopic
pancreas (HP) is the second most common pancreatic congenital
anomaly after divisum.
1 It has an incidence of 0.6–15% in autopsy
series and is found incidentally in 1 of 500 laparotomies.
1 HP is
located within the upper gastrointestinal tract in 70–90% of
cases.
1 Histologically, the aberrant pancreatic tissue may contain
all elements of normal pancreatic tissue such as acini, ducts and
islet cells.
2 Consequently, HP may demonstrate the full range of
pancreatic pathologies including pancreatitis (acute and chronic)
as well as benign and malignant neoplastic transformations.
2
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Figure 1 Partial gastrectomy specimen. (A) The submucosal bulge. (B) Cross-sectional view of the resected stomach showing the heterotopic
pancreatic tissue (arrow) within the layers of the gastric wall.
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